Regulus Therapeutics Completes Enrollment in Phase 1b Kidney Disease Drug Trial

MT Newswires Live10-08

Regulus Therapeutics (RGLS) said Tuesday it has completed enrollment in the phase 1b multiple-ascending dose trial of its investigational drug RGLS8429 drug to treat patients with autosomal dominant polycystic kidney disease, or ADPKD.

The company said 26 patients have been enrolled in the fourth and final cohort in the dosing trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS8429 in adult ADPKD patients compared to placebo.

Regulus said it expects topline data from a substantial number of the fourth cohort patients to be available early next year.

The company said results from each of the prior three cohorts in the study were positive, showing "continued evidence of a mechanistic dose response based on increase in urinary polycystins."

Shares of Regulus were down more than 5% in recent trading.

Price: 1.62, Change: -0.09, Percent Change: -5.26

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473472999?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 23:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473472999","market":"sg","top_or_hot":-1,"title":"Regulus Therapeutics Completes Enrollment in Phase 1b Kidney Disease Drug Trial","media":"MT Newswires Live","content":"<html><body><p> Regulus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RGLS) said Tuesday it has completed enrollment in the phase 1b multiple-ascending dose trial of its investigational drug RGLS8429 drug to treat patients with autosomal dominant polycystic kidney disease, or ADPKD.</p><p>The company said 26 patients have been enrolled in the fourth and final cohort in the dosing trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS8429 in adult ADPKD patients compared to placebo.</p><p>Regulus said it expects topline data from a substantial number of the fourth cohort patients to be available early next year.</p><p>The company said results from each of the prior three cohorts in the study were positive, showing \"continued evidence of a mechanistic dose response based on increase in urinary polycystins.\"</p><p>Shares of Regulus were down more than 5% in recent trading.</p><p>Price: 1.62, Change: -0.09, Percent Change: -5.26</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regulus Therapeutics Completes Enrollment in Phase 1b Kidney Disease Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegulus Therapeutics Completes Enrollment in Phase 1b Kidney Disease Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 23:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regulus Therapeutics (RGLS) said Tuesday it has completed enrollment in the phase 1b multiple-ascending dose trial of its investigational drug RGLS8429 drug to treat patients with autosomal dominant ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2473472999","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473472999","pubTimestamp":1728401558,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regulus Therapeutics  said Tuesday it has completed enrollment in the phase 1b multiple-ascending dose trial of its investigational drug RGLS8429 drug to treat patients with autosomal dominant polycystic kidney disease, or ADPKD.The company said 26 patients have been enrolled in the fourth and final cohort in the dosing trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS8429 in adult ADPKD patients compared to placebo.Regulus said it expects topline data from a substantial number of the fourth cohort patients to be available early next year.The company said results from each of the prior three cohorts in the study were positive, showing \"continued evidence of a mechanistic dose response based on increase in urinary polycystins.\"Shares of Regulus were down more than 5% in recent trading.Price: 1.62, Change: -0.09, Percent Change: -5.26","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RGLS":"Regulus Therapeutics Inc"},"translate_title":"Regulus Therapeutics完成1b期肾病药物试验入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGLS":1},"content_text":"Regulus Therapeutics (RGLS) said Tuesday it has completed enrollment in the phase 1b multiple-ascending dose trial of its investigational drug RGLS8429 drug to treat patients with autosomal dominant polycystic kidney disease, or ADPKD.The company said 26 patients have been enrolled in the fourth and final cohort in the dosing trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS8429 in adult ADPKD patients compared to placebo.Regulus said it expects topline data from a substantial number of the fourth cohort patients to be available early next year.The company said results from each of the prior three cohorts in the study were positive, showing \"continued evidence of a mechanistic dose response based on increase in urinary polycystins.\"Shares of Regulus were down more than 5% in recent trading.Price: 1.62, Change: -0.09, Percent Change: -5.26","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473472999"}